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This Finnish population-based study, mean age 46 years, evaluates the association of high-sensitivity C-reactive protein (hs-CRP),
interleukin-1 receptor antagonist (IL-1Ra), and adiponectin with the NCEP and IDF deﬁnitions of metabolic syndrome (MetS).
Adiponectin levels were higher, hs-CRP and IL-1Ra levels lower in subjects without MetS compared to subjects with MetS. If MetS
was present according to both IDF and NCEP criteria, BMI, waist, triglycerides, hs-CRP, and IL-1Ra were signiﬁcantly higher
compared to subjects who had MetS according to either only IDF or only NCEP criteria. The hs-CRP, IL-1Ra, and adiponectin
linearly correlated with the number of the components of MetS according to both deﬁnitions. Decreased levels of adiponectin and
increased levels of hs-CRP and IL-1Ra are tightly associated with the components of MetS. Individuals who had MetS according
to both criteria had the most adverse changes in cardiovascular risk factors.
Copyright © 2007 Juha Saltevo et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Metabolic syndrome (MetS) means a clustering of multiple
cardiovascular risk factors in an individual. Several deﬁni-
tions of this syndrome have been presented. The ﬁrst deﬁ-
nition was given by the World Health Organization (WHO)
in 1999. The primary aim of this deﬁnition was to identify
individuals with high risk for cardiovascular disease (CVD)
[1].
The National Cholesterol Education Program (NCEP)
AdultTreatmentPanelIIIintroducedanewdeﬁnitionforthe
MetS in 2001 [2]. This deﬁnition was modiﬁed in 2004 when
thecutoﬀpointforthefastingglucoselevelwasloweredfrom
≥6.1mmol/L to ≥5.6mmol/L based on the new deﬁnition of
impaired fasting glucose of the American Diabetes Associa-
tion [3]. The purpose of the NCEP deﬁnition was to identify
people who are at high long-term risk for CVD and/or type-
2 diabetes. The most recent deﬁnition has been presented by
the International Diabetes Foundation (IDF) in 2005 [4, 5].
It is a modiﬁcation from the NCEP deﬁnition, but in con-
trast to the NCEP deﬁnition, abdominal obesity (large waist)
is mandatory for the MetS in the IDF deﬁnition, because it
was considered to be the most important etiological compo-
nent of the syndrome.
Adipose tissue has also shown to be an active endocrine
organ secreting many hormones and mediators regulating
glucose metabolism and the risk of CVD. One of these hor-
mones is adiponectin that has been found to be decreased
in individuals with obesity, the MetS, and type-2 diabetes
[6, 7]. Adiponectin does not modulate only glucose and lipid
metabolism, but also the immune system. Thus, adiponectin
is currently recognized as an anti-inﬂammatory adipocy-
tokine [8].
Obesity is an inﬂammatory condition which may lead
to chronic activation of the innate immune system, which
in turn could cause a progressive impairment of glucose
tolerance and lead to diabetes or CVD [9, 10]. In agree-
ment with this hypothesis increased levels of high-sensitivity
C-reactive protein (hs-CRP), an acute-phase protein, has
shown to predict coronary heart disease (CHD) [11–13]a n d2 Mediators of Inﬂammation
the development of the MetS [14], type-2 diabetes [15], and
the development of both CVD and type-2 diabetes [16, 17].
In a 12-year follow-up study including elderly women, an in-
crement of 1pg/ml of baseline hs-CRP level was associated
with a 37% increase in the risk of the MetS deﬁned by the
NCEP criteria [18]. Based on these studies, several investi-
gators have suggested that high hs-CRP should be added in
the deﬁnition of the MetS because it connects proinﬂamma-
tion, central adiposity, and MetS, and could be measured in
clinical practice [19, 20].
Interleukin-1 receptor antagonist (IL-1Ra), a naturally
occurring antagonist of the proinﬂammatory cytokines IL-
1α and IL-1β, reﬂects inﬂammatory response. It is a natural
compensatory mechanism for IL-1-induced disease process
[21], and it is elevated in subjects with the MetS [22]. IL-
1Ra has anti-inﬂammatory properties, because it competi-
tively binds to membrane receptors of IL-1β. It is also an
acute phase reactant produced by liver during the inﬂam-
matory state [23]. Thus, low circulating concentrations of
adiponectin and high levels of hs-CRP and IL-1Ra are mark-
ers of a proinﬂammatory state.
No previous studies have been published on the role of
hs-CRP, IL-1Ra, and adiponectin in relation to diﬀerent def-
initions of the MetS in the same population. The aim of
the present study was to evaluate the inﬂammatory diﬀer-
ences and associations between the inﬂammatory markers
and adiponectin with the MetS according to the NCEP and
the IDF deﬁnitions.
2. MATERIALS AND METHODS
2.1. Subjects
The study population consisted of middle-aged Caucasian
subjects (N = 1294) born in 1942, 1947, 1952, 1957, and
1962 (the entire age group) in Pieks¨ am¨ aki, eastern Finland.
All participants gave an informed written consent. The study
protocol was approved by ethics comittee of the Kuopio Uni-
versity Hospital and the University of Kuopio.
Altogether 923 of 1294 subjects (71.3%) participated in
thiscross-sectionalstudyin1997-1998. Allparticipantsﬁlled
a standard questionnaire including questions about medica-
tion,smokinghabits,andphysicalactivity.Weexcludedfrom
statistical analysis 18 subjects (7 men and 11 women) with
hs-CRP concentrations ≥10.0mg/L to exclude possible cases
ofacuteinfectionsandotheroccultdiseases.Additionalthree
women were lost from statistical analysis because of missing
data for the components of the MetS.
2.2. Deﬁnitionsofthemetabolicsyndrome
MetS was deﬁned based on the criteria proposed by NCEP
[3]a n dI D F[ 4, 5]. According to the NCEP criteria, the MetS
was deﬁned as the presence of 3 or more of the following car-
diovascular risk factors: abdominal obesity (waist circumfer-
ence >102cm in men and >88cm in women), triglycerides
≥1.7mmol/L (150mg/dL) or drug treatment for dyslipi-
demia, HDL cholesterol <1.03mmol/L (40mg/dL) in men
and < 1.29mmol/L (50mg/dL) in women or drug treat-
ment for dyslipidemia, blood pressure ≥130/≥85mm Hg or
drug treatment for hypertension, and fasting plasma glucose
≥5.6mmol/L (100mg/dL) or treatment for diabetes.
According to the IDF criteria, the MetS was deﬁned to
be present in individuals who had central obesity (waist cir-
cumference ≥94cm in men and ≥80cm in women) plus any
2 of the following factors: triglycerides >1.7mmol/L or drug
treatment for dyslipidemia, HDL cholesterol <1.03mmol/L
in men and <1.29mmol/L in women or drug treatment
for dyslipidemia, blood pressure ≥130/≥85mm Hg or drug
treatment of previously diagnosed hypertension, and fasting
plasma glucose ≥5.6mmol/L or previously diagnosed and
treated type-2 diabetes.
2.3. Clinicalandlaboratorymethods
Height and weight were measured to the nearest 0.5cmand
0.1kg, respectively. BMI was calculated as weight (kg) di-
vided by height (m) squared. The waist was measured at the
midpoint between the lateral iliac crest and the lowest rib to
the nearest 1cm. Trained nurses measured blood pressure
(BP) twice in subjects at sitting position after a 15-minute
rest with a mercury sphygmomanometer. The latter value
was used in statistical analysis.
Fasting blood samples were drawn after 12 hours of fast-
ing. Plasma was separated by centrifugation for the deter-
mination of fasting insulin and the samples were frozen im-
mediately. Insulin was determined by Phadeseph insulin ra-
dioimmunoassay (RIA) 100 methods (Pharmacia Diagnos-
tics AB, Uppsala, Sweden). Glucose concentration was mea-
sured by automated colorimetric method (Peridochrom glu-
cose GOD-PAP, Boehringer, Germany). Serum cholesterol
and triglycerides were measured from fresh serum samples
with enzymatic colorimeter methods (CHOD-PAP, GPO-
PAP, Boehringer Mannheim GmbH, Germany). Serum HDL
cholesterol was measured using the same methods after the
precipitation of low-density cholesterol and very low-density
lipoprotein cholesterol by phosphotungstic acid and magne-
sium.
Serum adiponectin was determined with an enzyme im-
munoassay (human adiponectin ELISA Kit, B-Bridge Inter-
national Inc, Calif, USA). Plasma concentration of IL-1Ra
was measured with high-sensitivity assay kits from R&D Sys-
tems.hs-CRPwasmeasuredwithanImmuliteanalyzeranda
DPC high-sensitivity CRP assay (hs-CRP). Adiponectin, hs-
CRP, and IL-1Ra were measured in 2002 at the same time.
Before this measurement, the samples werefrozen andstored
at −70
◦C.
In this study, we used the quantitative insulin sensitivity
check index (QUICKI) as a marker of insulin sensitivity. It is
an alternative method to measure insulin sensitivity in large
population studies and was calculated as follows: QUICKI =
1/(log FPI + log FBG), where FPI = fasting plasma insulin
level expressed as mU/l, and FBG = fasting plasma glucose
level expressed as mg/dL [24].
2.4. Statisticalanalysis
The results are expressed as mean ± standard deviation
(SD). Conﬁdence intervals for the means were obtained byJuha Saltevo et al. 3
Table 1: Demographic, clinical, and biochemical characteristics of the study population.
Variables Men (N = 405) Women (N = 497) P-value
Mean (SD) Mean (SD)
Demographic
Age, years 46 (6) 46 (6)
Body mass index, kg/m2 26.7 (3.8) 26.3 (4.9) .15
Waist, cm 93.8 (10.6) 83.3 (12.2) <.001
Clinical
Blood pressure, mmHg
Systolic 137 (17) 131 (17) <.001
Diastolic 84 (10) 79 (9) <.001
Biochemical
HDL cholesterol, mmol/L 1.3 (0.3) 1.5 (0.3) <.001
Triglycerides, mmol/L 1.7 (1.3) 1.2 (0.6) <.001
FP-glucose, mmol/L 5.9 (0.6) 5.6 (0.5) <.001
FP-insulin, mU/L 10.7 (5.9) 9.8 (6.5) .033
hs-CRP, pg/ml 1.3 (1.5) 1.5 (1.7) .035
IL-1Ra, pg/ml 172 (131) 192 (167) .16
Adiponectin, μg/ml 4.9 (2.7) 7.9 (4.4) <.001
HDL = high-density lipoprotein, hs-CRP = high-sensitivity C-reactive protein, IL-1Ra = interleukin-1 receptor antagonist, SD = standard deviation.
bias-corrected and accelerated bootstrapping (5000 replica-
tions).Statisticalcomparisonbetweengroupswasperformed
by t-test or analysis of variance (ANOVA) with bootstrap-
type tests, when appropriate. Bootstrap-based multiplicity
adjustment will be applied to correct levels of signiﬁcance
for multiple testing when appropriate [25]. The agreement
between the deﬁnitions was determined by the kappa statis-
tic (κ). The level of agreement is considered poor if κ<0.20,
fair if κ = 0.21–0.40, moderate if κ = 0.41–0.60, substantial
if κ = 0.61–0.80, and very good if κ>0.80 [26].
3. RESULTS
Altogether 923 of 1294 invited subjects (71.3%) participated
inthisstudy.Table 1 presentsdemographic,clinical,andbio-
chemical characteristics of study subjects. Waist, blood pres-
sure, triglyceride, and glucose levels were higher and HDL
cholesterol concentrations lower in men than in women (P<
.001). Median adiponectin concentration was lower in men
t h a ni nw o m e n( 4 . 9v e r s u s7 .9μg/ml, P<. 001), whereas me-
dian hs-CRP was higher in women than in men (1.5 versus
1.3pg/ml,P = .035).
Among the 923 participants, the prevalence of the MetS
according to the IDF deﬁnition was 38% in men and 34% in
women. According to the NCEP criteria, the corresponding
numbers were 34% in men, and 27% in women. In women,
the agreement (κ) between the IDF and NCEP criteria was
0.75 (95% Cl 0.68 to 0.81) and in men 0.60 (95% Cl 0.52 to
0.68).
Table 2 shows that adiponectin levels were signiﬁcantly
(P<. 001) lower in males and females in subjects with the
Mets compared to subjects without Mets, independently of
the deﬁnition used. On the other hand, the levels of hs-CRP
and IL-1Ra were signiﬁcantly higher in subjects with the
MetS compared to subjects without the MetS in both gen-
ders.
Insulin sensitivity index measured by QUICKI was sig-
niﬁcantly higher in subjects without the MetS than with
MetS according to both deﬁnitions without any gender dif-
ference(IDFcriteria:0.35±0.18 versus 0.32±0.02, P<. 001;
NCEP criteria: 0.35 ±0.02 versus 0.32 ± 0.02, P<. 001).
Table 3 shows that when the MetS was present according
to bothIDF and NCEP deﬁnitions, waist and triglyceride lev-
els weresigniﬁcantlyhigher andHDL cholesterollower com-
pared to those who had the MetS just according to the IDF,
but not NCEP criteria, or MetS just according to the NCEP
criteria, but not IDF-criteria in both genders.
Table 4 shows that the mean hs-CRP level was 1.00pg/ml
in men having the MetS according only to the NCEP def-
inition, 1.52pg/ml having the MetS according only to the
IDF deﬁnition, and 1.73pg/ml when both deﬁnitions (IDF
and NCEP) simultaneously were present (P = .033 be-
tween groups and linearity 0.020). The mean hs-CRP level
in women was 0.81, 1.45, and 2.62pg/ml (P<. 001 between
the groups, linearity 0.010), respectively. The corresponding
levels of adiponectin and IL-1Ra are also shown in Table 4.
Figures 1–3 show the correlation of adiponectin, hs-CRP,
and IL-1Ra with the number of the components of the MetS
present (0-1, 2-3, 4-5) according to the IDF and the NCEP4 Mediators of Inﬂammation
Table 2: Adiponectin, interleukin-1 receptor antagonist (IL-1Ra), and high-sensitivity C-reactive protein (hs-CRP) levels according to the
IDF and the NCEP deﬁnitions of metabolic syndrome in men and women.
Deﬁnitions of metabolic syndrome
IDF NCEP
Not present Present P-value† Not present Present P-value†
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Men
No of subjects, (%) 250 (62) 155 (38) 268 (66) 137 (34)
Adiponectin, μg/ml 5.31 (2.75) 4.15 (2.46) <.001 5.29 (2.83) 4.04 (2.23) <.001
IL-1Ra, pg/ml 145 (72) 217 (182) <.001 153 (84) 210 (187) <.001
hs-CRP, pg/ml 1.10 (1.39) 1.67 (1.62) <.001 1.18 (1.44) 1.57 (1.61) 0.04
Women
Number 328 (66) 169 (34) 362 (73) 135 (27)
Adiponectin, μg/ml 8.44 (4.69) 6.89 (3.72) <.001 8.34 (4.63) 6.77 (3.67) <.001
IL-1Ra, pg/ml 145 (77) 284 (242) <.001 154 (106) 294 (243) <.001
hs-CRP, pg/ml 1.10 (1.26) 2.32 (2.09) <.001 1.15 (1.26) 2.49 (2.24) <.001
† Bootstrap type t-test with bootstrap-based multiplicity adjustments (5000 replications).
95% conﬁdence interval obtained by bias-corrected and accelerated bootstrapping (5000 replications).
Table 3: Demographic, clinical, and biochemical characteristics of subjects with the metabolic syndrome.
Variables
Deﬁnitions of the metabolic syndrome P-value between
Only NCEP Only IDF Both IDF and NCEP
Male Female Male Female Male Female Males Females
(N = 28) (N = 10) (N = 46) (N = 44) (N = 109) (N = 125)
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Demographic
Age, years 48 (7) 49 (5) 48 (6) 47 (6) 47 (6) 48 (6) 0.87 0.76
Body mass index, kg/m2 25.7 (1.9) 24.1 (1.9) 27.1 (1.7) 27.2 (2.3) 30.8 (3.4) 31.5 (5.1) <.001 <.001
Waist, cm 89 (4) 76 (4) 97 (2) 85 (2) 106 (9) 97 (11) <.001 <.001
Clinical
Blood pressure, mmHg
Systolic 141 (12) 134 (6) 142 (19) 134 (16) 144 (16) 141 (16) .61 .035
Diastolic 87 (11) 80 (10) 87 (9) 82 (7) 89 (9) 85 (7) .32 .038
Biochemical
HDL cholesterol, mmol/L 1.2 (0.3) 1.2 (0.2) 1.4 (0.3) 1.5 (0.4) 1.1 (0.2) 1.3 (0.3) <.001 .001
Triglycerides, mmol/L 2.5 (1.5) 1.6 (0.6) 1.6 (0.9) 1.3 (0.6) 2.4 (1.8) 1.7 (0.8) .007 .004
FP-glucose, mmol/L 6.1 (0.6) 5.8 (0.4) 6.1 (0.5) 5.9 (0.6) 6.3 (0.7) 6.0 (0.6) .061 .23
HDL = high-density lipoprotein.
criteria in both genders (P for linearity <.001 in all deﬁni-
tions).
4. DISCUSSION
Our study shows that proinﬂammatory cytokines and
adiponectin are likely to be central components of the MetS.
Cytokine levels were higher and adiponectin levels lower in
subjects who had the MetS according to both deﬁnitions
(IDF, NCEP) compared to subjects who had the MetS ac-
cording to only one deﬁnition. Furthermore, the only-IDF
deﬁnitiongroupoftheMetShadhigherlevelsofhs-CRPand
IL-1Ra compared to the group with only-NCEP deﬁnition,
probably due to abdominal obesity as the central criterion
for the syndrome. The same stronger relationship with the
IDF deﬁnition compared to the NCEP was found in Chinese
populationwithhs-CRP[27].SubjectswiththeMetSdeﬁned
according to only NCEP criteria had quite normal levels of
adiponectin and inﬂammatory markers, which may indicate
that these subjects are not at so high risk for CVD and/orJuha Saltevo et al. 5
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Figure 1: Relationship between adiponectin and the number of the components of the metabolic syndrome according to the IDF and NCEP
criteria (95% conﬁdence intervals obtained by bias-corrected and accelerated bootstrapping (5000 replications)).
diabetes. On the other hand, the levels of triglycerides were
higher and HDL cholesterol tended to be lower in this only
NCEP-population. In a recent study, quite similar risk for
CVD and diabetes were observed in subjects having the MetS
according to the IDF, NCEP, and WHO deﬁnitions [28].
Excess adipose tissue can contribute to inﬂammation in
several ways. First, ectopic fat storage induces lipotoxicity
promoting intracellular inﬂammatory response or altered
adipokine production [29]. Second, hypoadiponectinemia
may result by interactions of genetic factors in the adipo-
nectin gene itself and environmental factors causing obesity,
whichleadstoinsulinresistanceandMetS[8].IntheADOPT
study including recently diagnosed, drug na¨ ıve type-2 dia-
betic subjects inﬂammatory markers were strongly related to
the numberof the components of the MetS [30]. Anyhow, in
several other studies, diﬀerent measures of insulin resistance
and cardiometabolic risk factors have correlated signiﬁcantly
with intra-abdominal adiposity [31–33].
Our study conﬁrmed that levels of adiponectin, hs-CRP,
and IL-1Ra were similarly and linearly correlated with the
number of components of the MetS according to the IDF
and NCEP deﬁnitions in both genders. Similar results have
been reported previously with respect to levels of hs-CRP
[30, 34, 35] and adiponectin [36–39]i nd i ﬀerent popula-
tions. In the Finnish Diabetes Prevention Study, hs-CRP was
the best immunological predictor for the progression from
impaired glucose tolerance to overt type-2 diabetes [40]. IL-
1Ra has been shown to be the most sensitive marker of cy-
tokine response in the prediabetic state among the oﬀspring
of type-2 diabetic patients, probable protecting human beta-
cells from glucose-induced functional impairment [41], and
the levels of IL-1Ra are decreased when type-2 diabetes de-
velops [42]. However, longitudinal studies are missing to
indicate whether or not IL-1Ra levels predict the develop-
ment of diabetes or CVD. Our ﬁndings show that accord-
ing to any deﬁnition of the MetS, conventional cardiovascu-
lar risk factors, insulin resistance measured by QUICKI, low
adiponectin, and high-level proinﬂammatory markers clus-
ter in the same individuals.
The prevalence of the MetS was 38% in men and 34% in
women according to the IDF deﬁnition, and 34% and 27%,
respectively, according to the NCEP deﬁnition. Our results
agree with previous results from Finland [43]. The preva-
lence of MetS deﬁned by IDF was somewhat higher, espe-
cially in women. On the other hand, the level of agreement
between both deﬁnitions was better in women. Mostly both
deﬁnitions of the MetS identiﬁed the same high-risk indi-
viduals, but the IDF deﬁnition identiﬁed more reliably indi-
viduals with more unfavourable proinﬂammatory parame-
ters than did the NCEP deﬁnition. Subjects having the MetS
according to both IDF and NCEP criteria had signiﬁcantly
higher BMI, waist circumference, triglycerides and inﬂam-
matory markers and lower levels of adiponectin and HDL
cholesterol compared to subjects having the MetS according
to only either IDF or NCEP criteria.
The strength of our study is that it includes a substan-
tial number of subjects selected from 5 diﬀerent age groups
without any exclusion criteria in the same town. Therefore,6 Mediators of Inﬂammation
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Figure 2: Relationship between high-sensitivity C-reactive protein (hs-CRP) and the number of the components of the metabolic syn-
drome according to the IDF and NCEP criteria (95% conﬁdence interval obtained by bias-corrected and accelerated bootstrapping (5000
replications)).
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Figure 3: Relationship between interleukin-1 receptor antagonist (IL-1Ra) and the number of components of the metabolic syndrome
according to the IDF and NCEP criteria (95% conﬁdence interval obtained by bias-corrected and accelerated bootstrapping (5000 replica-
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Table 4: Levels of adiponectin, interleukin-1 receptor antagonist (IL-1Ra), and high-sensitivity C-reactive protein (hs-CRP) according to
the IDF and the NCEP deﬁnitions of the metabolic syndrome, according to gender.
Variables Deﬁnitions of metabolic syndrome P-value†
Only NCEP Only IDF Both IDF and NCEP Between group Linearity
Men
Number 28 46 109
Adiponectin, μg/ml, mean (SD) 4.91 (2.54) 4.94 (3.05) 3.81 (2.10) .021 .034
IL-1Ra, pg/ml, mean (SD) 140 (73) 189 (118) 228 (203) .032 .018
Hs-CRP, pg/ml, mean (SD) 1.00 (0.98) 1.52 (1.40) 1.73 (1.70) .033 .020
Women
Number 10 44 125
Adiponectin, μg/ml, mean (SD) 8.48 (5.08) 7.62 (4.18) 6.63 (3.52) .25 .14
IL-1Ra, pg/ml, mean (SD) 146 (84) 222 (216) 305 (248) .004 .044
hs-CRP, pg/ml, mean (SD) 0.81 (1.06) 1.45 (1.18) 2.62 (2.26) <.001 .010
† Bootstrap-type ANOVA.
wecouldreliablycomparethecorrelationsofIL-1Rawithhs-
CRP and adiponectin in the same study population, which
is fairly homogeneous regarding age, BMI, and origin. We
could demonstrate that IL-Ra is correlated with Mets simi-
larly as hs-CRP and adiponectin. The limitation of our study
is that we measured total adiponectin, but not the high
molecular weight (HMW) multimer of adiponectin, which
has been shown to be a better marker for the MetS than is
the total adiponectin level [44, 45].
5. CONCLUSIONS
We conclude that decreased levels of adiponectin and in-
creased levels of hs-CRP and IL-1Ra possibly reﬂect the same
phenomenon, and correlate linearly with the number of the
componentsoftheMetSaccordingtotheIDFandNCEPdef-
initions. The levels of inﬂammatory markers (hs-CRP and
IL-1Ra)arehigheramongpatientswithMetSdeﬁnedonlyby
the IDF deﬁnition compared to the only NCEP deﬁned ones.
More longitudinal follow-up studies are needed to investi-
gate whether or not these new markers of the MetS increase
the predictive power with respect to future risk of type-2 di-
abetes and CVD in diﬀerent populations.
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